Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSupportive Therapy, ToxicityProtocol groupImmunodeficienciesDiseaseAntibody Deficiency, PrimarySubgroupICD10MeSHPrimary Immunodeficiency DiseasesSequenceRHUH(800/1600/2400)/SCIgG(10/20/30), prim. Antibody deficiency, C1 (PID1726) -|- RHUH2400/SCIgG30, C2+ (PID1731)Antineoplastic therapySubstanceSubstanceSubstanceSubstanceAnzahl Substanzen RadiotherapySupportive therapySubstanceHuman immunoglobulin (SCIg)Recombinant human hyaluronidaseSubstanceHuman immunoglobulin (SCIg)Recombinant human hyaluronidaseSubstanceHuman immunoglobulin (SCIg)Recombinant human hyaluronidaseSubstanceHuman immunoglobulin (SCIg)Recombinant human hyaluronidaseAnzahl Substanzen2Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationTherapy phaseTherapy intentiondisease controlsupportiveRisksAllergic ReactionHeadachePain only studiesPublicationAuthorWasserman RLDiseasePrimäre HypogammaglobulinämieOriginAllergy/Immunology Research Center of North Texas, Dallas, USAProtocols in Revision 2 protocols foundRecombinant Human Hyaluronidase (800/1600/2400) / Subcutaneous Immunoglobulin-G (10/20/30), Primary Antibody Deficiency, Cycle 1 (PID1726 V1.0)Recombinant Human Hyaluronidase 2400 / Subcutaneous Immunoglobulin-G 30, Primary Antibody Deficiency, Cycle 2+ (PID1731 V1.0)
